European Commission logo
English English
CORDIS - EU research results

Article Category

Content archived on 2023-03-06

Article available in the following languages:


First series of biomaterial development and validation projects defined for Angioscaff project

The first series of collaborative biomaterial development and biomaterial validation projects have now been defined for the Angioscaff project. Coordinated by Professor Jeffrey Hubbell from the EPFL, and financially co-supported by the European Commission through the 7th Framework Programme Nanosciences priority, the Angioscaff project (Angiogenesis inducing bioactive and bio-responsive scaffolds for tissue engineering) has defined the first series of projects that will be performed to develop new biomaterials in combination with morphogens for tissue regeneration.

With a primary focus on combining the two components to stimulate blood vessel development; the first step towards regenerating damaged or diseased tissue into a fully functional and healthy organ, the project partnership has now fully defined a series of biomaterials to be combined with specific morphogens in the first series of developmental studies targeted for specific degenerative diseases. Some key highlights of these projects include: • Professor Kevin Shakesheff (University of Nottingham) and Professor Jons Hilborn (University of Uppsala) exploring optimal combinations of biomaterials for more flexible tissue regeneration strategies, with a specific focus on bone tissue, working with Professor Heinz Redl (LBIT Vienna). • Professor Carsten Werner (IPF Dresden), Professor Matthias Lutolf (EPFL), Professor Dror Seliktar (Technion) co-developing novel biomaterials with specific cell adhesion properties • Professor Jeffrey Hubbell (EPFL) and Professor Elisabetta Dejana (IFOM, Milan) addressing VE-Cadherin for blood vessel stablisation • Professor Paolo Bianco (Science Park Rome), Professor Carsten Werner, Professor Matthias Lutolf and Professor Jeffrey Hubbell are exploring cutting-edge approaches to stimulate blood vessel stem cells already present in damaged tissue to initiate the repair process • Professor Sabine Eming (University of Cologne) and Professor Jeffrey Hubbell assessing the optimal methods to present specific morphogens and factors for stimulating repair of the skin following serious injury. • Professor Giulio Cossu (Science park Rome), Professor Jeffrey Hubbell and Professor Dror Seliktar are developing highly specialized approaches for optimizing skeletal muscle stem cell transplantation and creating new muscle growth. • Professor Gianluigi Condorelli (Gruppo Multi Medica), Professor Dror Seliktar and Professor Jeffrey Hubbell are exploring the best way to treat heart disease via cells and biomaterials combined. • Professor Thomas Eschenhagen (University of Hamburg-Eppendorf), Professor Jeffrey Hubbell with selected companies are complimenting this with new strategies to deliver growth factors to the damaged heart for cell free tissue repair. Participating in all of these projects are select companies including Baxter Innovation, Smith and Nephew, Bayer Innovations, Kuros, Intercytex, NeuroNova and Miltenyi, who perform active research collaborations as well as ensuring that any therapeutics with high promise are efficiently translated to the patients and market place. For more information please visit: About Angioscaff Coordinated by Professor Jeffrey Hubbell from the Ecole Polytechnique Federale de Lausanne, with over 30 groups from leading European and Israeli academic centres, small industries and large pharma companies in full partnership. The specific strategies being implemented are: Radical innovations in state-of-the-art biomaterials, Design and production of advanced bioactive scaffolds enabling internal growth of tissue and the site specific delivery of bioactive signaling factors, that control cell differentiation, Injectable biomaterials and effective delivery device design that can induce angiogenesis in the body, Development of bioresorbable, highly porous, and structurally sound tissue-engineered scaffolds, Functionalized biomaterials that have direct influence on cell behavior, Bioactive scaffolds with broad applicability for complex tissues for the stimulating the regeneration of the Peripheral vascular system; Cardiovascular system; Bone; Skin; Central nervous system; Peripheral Nervous system or Muscle after damage or because of disease. The unique combination of expertise and resources bringing together globally recognised specialists, to achieve these objectives could only be performed via the financial support of the European Commission through the Seventh framework Programme Nanosciences, Nanotechnologies, Materials and Production priority who are providing nearly 12 million euros of funding from 2008 to 2012.


United Arab Emirates, Austria, Australia, Belgium, Bulgaria, Cyprus, Czechia, Germany, Denmark, Estonia, Greece, Spain, Finland, France, Hong Kong, Hungary, Ireland, Italy, Lithuania, Luxembourg, Latvia, Malta, Netherlands, Poland, Portugal, Romania, Russia, Saudi Arabia, Sweden, Slovenia, Slovakia, United Kingdom, United States, South Africa